Concepedia

The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE

Marco Maccauro, Mariarosaria Cuomo, Matteo Bauckneht, Matteo Bagnalasta, S. Mazzaglia, Federica Scalorbi, Giovanni Argiroffi, Margarita Kirienko, Alice Lorenzoni, G Aliberti,

European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 15 citations · 26 references

DOI

Concepts

References

26

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology · 2017 · 3.4K citations · Full text

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3K citations · Full text

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

The Lancet Oncology · 2021 · 487 citations

, , +10

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Rodney J. Hicks, Dik J. Kwekkeboom, Eric P. Krenning et al. · Neuroendocrinology · 2017 · 321 citations

, , +16